Eric O Freed

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi HIV-1 gag proteins: diverse functions in the virus life cycle
    E O Freed
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 20892 0460, USA
    Virology 251:1-15. 1998
  2. ncbi Mechanisms of enveloped virus release
    Eric O Freed
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Bg. 535/Rm. 124, Frederick, MD 21702-1201, USA
    Virus Res 106:85-6. 2004
  3. ncbi The HIV-TSG101 interface: recent advances in a budding field
    Eric O Freed
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
    Trends Microbiol 11:56-9. 2003
  4. ncbi Retroviruses 2004: review of the 2004 Cold Spring Harbor Retroviruses Conference
    Eric O Freed
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bg 535 Rm 108, Frederick, MD 21702 1201, USA
    Retrovirology 1:25. 2004
  5. ncbi Viral late domains
    Eric O Freed
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA
    J Virol 76:4679-87. 2002
  6. ncbi Virology. Rafting with Ebola
    Eric O Freed
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0460, USA
    Science 296:279. 2002
  7. ncbi The cell biology of HIV-1 and other retroviruses
    Eric O Freed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    Retrovirology 3:77. 2006
  8. ncbi HIV-1 Gag: flipped out for PI(4,5)P(2)
    Eric O Freed
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702-1201, USA
    Proc Natl Acad Sci U S A 103:11101-2. 2006
  9. ncbi Functional role of Alix in HIV-1 replication
    Ken Fujii
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21701 1201, USA
    Virology 391:284-92. 2009
  10. ncbi Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, Bldg 535, RM 108, Frederick, MD 21702 1201, USA
    J Virol 82:9776-81. 2008

Collaborators

Detail Information

Publications70

  1. ncbi HIV-1 gag proteins: diverse functions in the virus life cycle
    E O Freed
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 20892 0460, USA
    Virology 251:1-15. 1998
    ..This review briefly summarizes our current understanding of how HIV-1 Gag proteins function in the virus life cycle...
  2. ncbi Mechanisms of enveloped virus release
    Eric O Freed
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Bg. 535/Rm. 124, Frederick, MD 21702-1201, USA
    Virus Res 106:85-6. 2004
  3. ncbi The HIV-TSG101 interface: recent advances in a budding field
    Eric O Freed
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
    Trends Microbiol 11:56-9. 2003
    ..The structure of the PTAP-TSG101 binding site has recently been solved, providing valuable insights into this crucial protein-protein interaction...
  4. ncbi Retroviruses 2004: review of the 2004 Cold Spring Harbor Retroviruses Conference
    Eric O Freed
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bg 535 Rm 108, Frederick, MD 21702 1201, USA
    Retrovirology 1:25. 2004
    ..While the most striking developments this year involved post-entry events and assembly/release, significant progress was made towards elucidating a number of aspects of the retroviral replication cycle...
  5. ncbi Viral late domains
    Eric O Freed
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA
    J Virol 76:4679-87. 2002
  6. ncbi Virology. Rafting with Ebola
    Eric O Freed
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0460, USA
    Science 296:279. 2002
  7. ncbi The cell biology of HIV-1 and other retroviruses
    Eric O Freed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    Retrovirology 3:77. 2006
    ..MEETING REPORT: The conference began with a keynote address from W. Sundquist on the biochemistry of HIV-1 budding. This presentation will be described in the section on Assembly and Release of Retroviruses...
  8. ncbi HIV-1 Gag: flipped out for PI(4,5)P(2)
    Eric O Freed
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702-1201, USA
    Proc Natl Acad Sci U S A 103:11101-2. 2006
  9. ncbi Functional role of Alix in HIV-1 replication
    Ken Fujii
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21701 1201, USA
    Virology 391:284-92. 2009
    ....
  10. ncbi Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, Bldg 535, RM 108, Frederick, MD 21702 1201, USA
    J Virol 82:9776-81. 2008
    ..We demonstrated that the ability of Vpu to counter the activity of CD317/BST-2/tetherin is markedly reduced by AME. These results indicate that AME interferes with the anti-CD317/BST-2/tetherin function of Vpu...
  11. ncbi Real-time visualization of HIV-1 GAG trafficking in infected macrophages
    Karine Gousset
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, USA
    PLoS Pathog 4:e1000015. 2008
    ..These data indicate that a population of Gag in infected macrophages remains sequestered internally and is presented to uninfected target cells at a virological synapse...
  12. ncbi Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, Bldg 535, RM 108, Frederick, MD 21702 1201, USA
    J Virol 84:3121-6. 2010
    ..We identified a new gp41 mutation, R236L, that results in cleavage of the gp41 tail by the PIR PR. These results highlight the central role of gp41 cleavage as the primary mechanism of AME resistance...
  13. ncbi Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function
    Dimiter G Demirov
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
    Proc Natl Acad Sci U S A 99:955-60. 2002
    ..These data demonstrate a link between the E2-like domain of TSG101 and HIV-1 L domain function, and indicate that TSG101 derivatives can act as potent and specific inhibitors of HIV-1 replication by blocking virus budding...
  14. ncbi HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 104:8467-71. 2007
    ..These data reveal that HIV-1 can escape from an inhibitor of viral entry by acquiring mutations that cause the cytoplasmic tail of gp41 to be cleaved by the viral protease...
  15. ncbi The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation
    Mary Ann Checkley
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute Frederick, Bldg 535 Rm 108, 1050 Boyles Street, Frederick, MD 21702 1201, USA
    Virology 400:137-44. 2010
    ..These data underscore the importance of full CA-SP1 processing for HIV-1 maturation and highlight the therapeutic potential of inhibitors that target this Gag cleavage event...
  16. ncbi Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression
    Ritu Goila-Gaur
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0460, USA
    J Virol 77:6507-19. 2003
    ..These results highlight the importance of TSG101 and the endosomal sorting pathway in virus budding and suggest that inhibitors can be developed that, like TSG-5', target HIV-1 without disrupting endosomal sorting...
  17. ncbi Structural basis for viral late-domain binding to Alix
    Sangho Lee
    Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health NIH, US Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Nat Struct Mol Biol 14:194-9. 2007
    ..Overexpression of the V domain inhibits HIV-1 release from cells. This inhibition of release is reversed by mutations that block binding of the Alix V domain to p6...
  18. ncbi Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation
    Anjali Joshi
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Bldg. 535/Rm. 108, Sultan Street, Frederick, MD 21702-1201, USA
    J Virol 80:7939-51. 2006
    ..The varied phenotypes of the mutants reported here provide novel insights into the interplay among Gag multimerization, membrane binding, virus assembly, CA dimerization, particle maturation, and virion infectivity...
  19. ncbi The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability
    Jiyang Jiang
    Section on Viral Gene Regulation, Program in Genomics of Differentiation, Eunice Kennedy Shriver National Institute of Child Health, National Institutes of Health, Building 6B, Room 216, 6 Center Drive, Bethesda, MD 20892 2780, USA
    Virology 421:253-65. 2011
    ..Collectively, these findings demonstrate that the linker region is essential for proper assembly and stability of cores and efficient replication...
  20. ncbi In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)
    Catherine S Adamson
    Virus-Cell Interaction Section, HIV Drug Resistance Program, NCI-Frederick, Bldg. 535/Rm. 108, 1050 Boyles Street, Frederick, MD 21702-1201, USA
    J Virol 80:10957-71. 2006
    ..These findings have implications for the ongoing development of PA-457 to treat HIV-1 infection in vivo...
  21. ncbi Molecular characterization of feline immunodeficiency virus budding
    Benjamin G Luttge
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, Bldg 535, RM 108, Frederick, MD 21702 1201, USA
    J Virol 82:2106-19. 2008
    ..Our data demonstrate that FIV relies predominantly on a Tsg101-binding PSAP motif in the C terminus of Gag to promote virus release in HeLa cells, and this budding mechanism is highly conserved in feline cells...
  22. ncbi Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment
    Anjali Joshi
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    J Virol 83:5375-87. 2009
    ....
  23. ncbi An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains
    Utpal M Munshi
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute Frederick, Frederick, Maryland 21702 1201, USA
    J Biol Chem 282:3847-55. 2007
    ..This study identifies a novel Alix-derived dominant negative inhibitor of HIV-1 release and Gag processing and provides quantitative information on the interaction between Alix and viral late domains...
  24. ncbi GGA and Arf proteins modulate retrovirus assembly and release
    Anjali Joshi
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    Mol Cell 30:227-38. 2008
    ..These findings identify the GGA proteins as modulators of HIV-1 release and the Arf proteins as critical cellular cofactors in retroviral Gag trafficking to the plasma membrane...
  25. ncbi SAR by oxime-containing peptide libraries: application to Tsg101 ligand optimization
    Fa Liu
    Laboratory of Medicinal Chemistry, CCR, NCI Frederick, Building 376 Boyles Street, Frederick, MD 21702, USA
    Chembiochem 9:2000-4. 2008
    ..Approximately 15-20-fold enhancement in binding affinity was achieved by this approach...
  26. ncbi Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)
    Catherine S Adamson
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, Frederick, MD 21702 1201, USA
    J Virol 83:4884-94. 2009
    ..These findings offer insights into the effect of PIR mutations on the evolution of BVM resistance in PI-experienced patients...
  27. ncbi Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body
    Akira Ono
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0460, USA
    J Virol 78:1552-63. 2004
    ..These data are consistent with a model for Gag targeting that postulates two different cellular binding partners for Gag, one on the plasma membrane and the other in the MVB...
  28. ncbi Effects of Gag mutation and processing on retroviral dimeric RNA maturation
    William Fu
    HIV Drug Resistance Program, National Cancer Institute at Frederick, P.O. Box B, Building 535, Room 336, Frederick, MD 21702, USA
    J Virol 80:1242-9. 2006
    ....
  29. ncbi Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat
    Catherine S Adamson
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    Retrovirology 7:36. 2010
    ..Recent clinical trials demonstrated that a significant proportion of HIV-1-infected patients do not respond to BVM. A patient's failure to respond correlated with baseline polymorphisms at SP1 residues 6-8...
  30. ncbi Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag
    Akira Ono
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Virology 360:27-35. 2007
    ..Altogether, these results are consistent with the hypothesis that cholesterol-enriched membrane microdomains promote HIV-1 particle production by facilitating both Gag-membrane binding and Gag multimerization...
  31. ncbi A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein
    Shixing Tang
    Viral Gene Regulation Section, Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Building 6B, Room 216, Bethesda, MD 20892 2780, USA
    Virology 359:105-15. 2007
    ..These findings describe a novel occurrence, namely suppression of a mutation in a hydrophobic residue that is critical for maintaining the structural integrity of CA and proper core assembly...
  32. ncbi Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1
    Ken Fujii
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    Nat Rev Microbiol 5:912-6. 2007
    ..Here, we focus on the use of host-cell factors during HIV-1 budding and highlight recent progress in our understanding of the role of one such factor, Alix, in both viral and cellular membrane budding and fission events...
  33. ncbi Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay
    Akira Ono
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, Maryland, USA
    J Virol 79:14131-40. 2005
    ..This report offers new insights into the association of HIV-1 Gag with membrane and with lipid rafts...
  34. ncbi Functional replacement of a retroviral late domain by ubiquitin fusion
    Anjali Joshi
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    Traffic 9:1972-83. 2008
    ..These findings demonstrate that ubiquitin can functionally compensate for the absence of a retroviral late domain and provide insights into the host-cell machinery engaged by ubiquitin during particle egress...
  35. ncbi Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane
    Akira Ono
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 101:14889-94. 2004
    ..These results demonstrate that PI(4,5)P2 plays a key role in Gag targeting to the plasma membrane and thus serves as a cellular determinant of HIV-1 particle production...
  36. ncbi Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants
    Abdul A Waheed
    Virus-Cell Interaction Section, HIV Drug Resistance Program, NCI-Frederick, National Institutes of Health, Frederick, Maryland 21702-1201, USA
    J Biol Chem 281:28699-711. 2006
    ..Our data define the target and mechanism of action of AME and provide support for the concept that cholesterol-binding compounds should be pursued as antiretroviral drugs to disrupt HIV-1 replication...
  37. ncbi Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion
    Himanshu Garg
    Membrane Structure and Function Section, Center for Cancer Research Nanobiology Program, NCI, National Institutes of Health, Frederick, Maryland 21702, USA
    J Biol Chem 282:16899-906. 2007
    ..These results may help to explain the mechanism of HIV-1 Env-induced T cell depletion...
  38. ncbi Human immunodeficiency virus type 1 assembly, release, and maturation
    Catherine S Adamson
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Adv Pharmacol 55:347-87. 2007
  39. ncbi HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice
    Paul W Keller
    Laboratory of Structural Biology Research, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Building 50, Room 1517, 50 South Drive, MSC 8025, Bethesda, MD 20892, USA
    J Virol 85:1420-8. 2011
    ..In both cases, the observed failure to assemble mature capsids correlates with the loss of infectivity...
  40. ncbi Defects in cellular sorting and retroviral assembly induced by GGA overexpression
    Anjali Joshi
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Maryland, USA
    BMC Cell Biol 10:72. 2009
    ..GGA overexpression led to the formation of large, swollen vacuolar compartments, which in the case of GGA1 sequestered HIV-1 Gag...
  41. ncbi HIV-1 and the host cell: an intimate association
    Eric O Freed
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Bldg. 535 Rm. 124 Sultan Street, Frederick, MD 21702-1201, USA
    Trends Microbiol 12:170-7. 2004
  42. ncbi Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction
    Young Jun Im
    Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 0580, USA
    Structure 18:1536-47. 2010
    ..However, the mutant alleles did rescue downregulation of endogenous EGF receptor. This demonstrates that the PSAP motif is not rate determining in EGF receptor downregulation under normal conditions...
  43. ncbi Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages
    Adam E Bennett
    Laboratory of Cell Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America
    PLoS Pathog 5:e1000591. 2009
    ..This potential mechanism for efficient virus trafficking between the cell surface and interior may represent a subversion of pre-existing vesicular machinery for antigen capture, processing, sequestration, and presentation...
  44. ncbi Peptide inhibitors of HIV-1 egress
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702, USA
    ACS Chem Biol 3:745-7. 2008
    ..An article in this issue reports on the application of a bacterial reverse two-hybrid strategy to identify a cyclic peptide that disrupts Gag-Tsg101 binding and suppresses HIV-1 particle release...
  45. ncbi Late domain-dependent inhibition of equine infectious anemia virus budding
    Miranda Shehu-Xhilaga
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA
    J Virol 78:724-32. 2004
    ....
  46. ncbi Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs
    Evguenia S Svarovskaia
    HIV Drug Resistance Program and AIDS Vaccine Program, Science Applications International Corporation Frederick, Inc, NCI Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
    J Biol Chem 279:35822-8. 2004
    ....
  47. ncbi Virus maturation as a new HIV-1 therapeutic target
    Catherine S Adamson
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Expert Opin Ther Targets 13:895-908. 2009
    ..The identification and development of lead maturation inhibitors are highlighted...
  48. ncbi HIV type 1 Gag as a target for antiviral therapy
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    AIDS Res Hum Retroviruses 28:54-75. 2012
    ..In this review, we summarize our current understanding of HIV-1 Gag and suggest some approaches for the development of novel antiretroviral agents that target Gag...
  49. ncbi Lipids and membrane microdomains in HIV-1 replication
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Virus Res 143:162-76. 2009
    ..In this review, we provide an overview of what is currently known about the involvement of lipids and membrane microdomains in HIV-1 replication...
  50. ncbi Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists
    Fa Liu
    Laboratory of Medicinal Chemistry, CCR, National Cancer Institute-Frederick/NIH, Bldg. 376 Boyles St, Frederick, MD 21702, USA
    Org Lett 8:5165-8. 2006
    ..This approach is demonstrated by application to Tsg101-binding compounds designed as potential HIV budding antagonists. [reaction: see text]..
  51. ncbi Influenza virus not cRAFTy enough to dodge viperin
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Cell Host Microbe 2:71-2. 2007
    ..Viperin appears to disrupt lipid rafts by suppressing the activity of farnesyl diphosphate synthase, a key enzyme in isoprenoid biosynthesis...
  52. ncbi Methods for the study of HIV-1 assembly
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program NCI Frederick, National Institutes of Health, Frederick MD, USA
    Methods Mol Biol 485:163-84. 2009
    ..Techniques have been developed in many laboratories to study each of the distinct phases of the HIV-1 assembly and release pathway. A number of these techniques are described in detail in this chapter...
  53. ncbi Retrovirus budding
    Dimiter G Demirov
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Bldg. 535/Rm. 124, Frederick, MD 21702-1201, USA
    Virus Res 106:87-102. 2004
    ..This review traces the history of L domain discovery and characterization, and highlights the relationship between L domain activity, retrovirus release, and the host endosomal sorting machinery...
  54. ncbi Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane
    Mathias Viard
    Center of Cancer Research Nanobiology Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA
    Biochemistry 47:1977-83. 2008
    ..These results shed light on the disposition of the HIV-1 gp41 CT with respect to the membrane. Moreover, our data have general implications for topology of membrane proteins and their in situ interactions with the lipid bilayer...
  55. ncbi FIV Gag: virus assembly and host-cell interactions
    Benjamin G Luttge
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Vet Immunol Immunopathol 134:3-13. 2010
    ..This review summarizes currently known interactions involving HIV-1 and FIV Gag that affect virus release, infectivity, and replication...
  56. ncbi Role of lipid rafts in virus replication
    Akira Ono
    Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, National Institutes of Health, Maryland 21702, USA
    Adv Virus Res 64:311-58. 2005
  57. ncbi Novel approaches to inhibiting HIV-1 replication
    Catherine S Adamson
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Antiviral Res 85:119-41. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  58. ncbi HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation
    Mary Ann Checkley
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, Frederick, MD 21702 1201, USA
    J Mol Biol 410:582-608. 2011
    ..Here, we review our current understanding of HIV-1 Env glycoprotein trafficking and incorporation into virions...
  59. ncbi The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner
    Dimiter G Demirov
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA
    J Virol 76:105-17. 2002
    ..The results described here define the role of p6 in virus replication in a wide range of cell types and reveal a strong cell type-dependent requirement for p6 in virus particle budding...
  60. ncbi Recent progress in antiretrovirals--lessons from resistance
    Catherine S Adamson
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702 1201, USA
    Drug Discov Today 13:424-32. 2008
    ....
  61. ncbi Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase
    Shixing Tang
    Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, Bethesda, Maryland 20892, USA
    J Virol 77:12592-602. 2003
    ..Thus, taken together with the almost complete absence of RT in mutant cores, these findings can account for the failure of the three CA mutants to synthesize viral DNA following virus entry into cells...
  62. ncbi Anti-HIV-1 Therapeutics: From FDA-approved Drugs to Hypothetical Future Targets
    Catherine S Adamson
    Virus Cell Interaction Section, HIV Drug Resistance Program National Cancer Institute at Frederick, Maryland, 21702 1201
    Mol Interv 9:70-4. 2009
    ..The current status of antiretroviral therapy and some of the promising new targets against which novel antiviral agents could be developed are discussed...
  63. ncbi Determinants of activity of the HIV-1 maturation inhibitor PA-457
    Feng Li
    Panacos Pharmaceuticals, 209 Perry Parkway, Gaithersburg, MD 20877, USA
    Virology 356:217-24. 2006
    ..These findings support and extend previous observations that PA-457 is a specific inhibitor of CA-SP1 cleavage and identify the CA-SP1 domain as the primary viral determinant for this novel inhibitor of HIV-1 replication...
  64. ncbi Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity
    Tsutomu Murakami
    Department of Immunology, Graduate School and Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa 903 0215, Japan
    J Virol 78:1026-31. 2004
    ..Interestingly, truncation of the gp41 cytoplasmic tail reversed the fusion defect. These results suggest that interactions between unprocessed Gag and the gp41 cytoplasmic tail suppress fusion...
  65. ncbi Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting
    Jamil S Saad
    Howard Hughes Medical Institute, Department of Chemistry and Biochemistry, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA
    J Mol Biol 382:434-47. 2008
    ....
  66. ncbi A cell-penetrating helical peptide as a potential HIV-1 inhibitor
    Hongtao Zhang
    Laboratory of Molecular Modeling and Drug Design, Lindsley F Kimball Research Institute of the New York Blood Center, 310 E 67th Street, New York, NY 10021, USA
    J Mol Biol 378:565-80. 2008
    ..This proof-of-concept cell-penetrating peptide may aid validation of capsid as an anti-HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to this protein...
  67. ncbi Point mutations in the HIV-1 matrix protein turn off the myristyl switch
    Jamil S Saad
    Howard Hughes Medical Institute and Department of Chemistry and Biochemistry, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA
    J Mol Biol 366:574-85. 2007
    ..This mutant binds PI(4,5)P(2) with twofold higher affinity compared with the native protein, suggesting a potential compensatory mechanism for membrane binding...
  68. ncbi A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41
    Melody R Davis
    Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232-2363, USA
    J Virol 80:2405-17. 2006
    ..Our results suggest that an altered interaction between the MA domain of Gag and the gp41 cytoplasmic tail leads to dissociation of gp120 from gp41 during HIV-1 particle assembly, thus resulting in impaired fusion and infectivity...
  69. ncbi Mechanisms of HIV type 1-induced cognitive impairment: evidence for hippocampal cholinergic involvement with overstimulation of the VIPergic system by the viral coat protein core
    Susan A Farr
    Geriatric Research Education and Clinical Center (GRECC, VA Medical Center, St. Louis, Missouri 63106, USA
    AIDS Res Hum Retroviruses 18:1189-95. 2002
    ....
  70. ncbi Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy
    Peter A Sklar
    AIDS 19:1109-11. 2005